The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Alex Ossola: U.S. hiring slowed in January, but remained solid in the last jobs ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

XBI is a biotech-focused ETF offering equal-weight exposure to U.S. biotechnology companies. The SPDR S&P Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index. XBI ...

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches ...

For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 by 9 percentage ...

In this podcast, Motley Fool analysts Tim Beyers and Karl Thiel discuss: To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check ...

Is the biotech industry truly out of its slump? This week on "The Readout LOUD," a biotech year in review and a look ahead to next year's trends.

Karen Marshall is the Executive Producer of GBH News' Morning Edition. Having alway dreamed of being an editor or writer, Karen got her start in radio at WROR in Boston as an intern, eventually ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...